SEOVF (Sernova Biotherapeutics) Total Assets: $1.12 Mil (As of Apr. 2026)


SEOVF Sernova Biotherapeutics Inc SEOVF
30 GF Score
Price $0.09
! 2 Warning Signs
View Full Analysis

What is Sernova Biotherapeutics Total Assets?

Sernova Biotherapeutics SEOVF -9.27% 30 Total Assets is $1.12 Mil as of Apr. 2026. GuruFocus rates SEOVF with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Sernova Biotherapeutics's Total Assets for the quarter that ended in Apr. 2026 was $1.12 Mil.

During the past 12 months, Sernova Biotherapeutics's average Total Assets Growth Rate was -74.40% per year. During the past 3 years, the average Total Assets Growth Rate was -43.10% per year. During the past 5 years, the average Total Assets Growth Rate was -18.70% per year. During the past 10 years, the average Total Assets Growth Rate was 13.90% per year.

During the past 13 years, Sernova Biotherapeutics's highest 3-Year average Total Assets Growth Rate was 351.50%. The lowest was -47.20%. And the median was -0.65%.

Total Assets is connected with ROA %. Sernova Biotherapeutics's annualized ROA % for the quarter that ended in Apr. 2026 was -1,014.37%. Total Assets is also linked to Revenue through Asset Turnover. Sernova Biotherapeutics's Asset Turnover for the quarter that ended in Apr. 2026 was 0.00.

Sernova Biotherapeutics  (OTCPK:SEOVF) Total Assets Explanation

Total Assets is connected with ROA %.

Sernova Biotherapeutics's annualized ROA % for the quarter that ended in Apr. 2026 is

ROA %=Net Income (Q: Apr. 2026 )/( (Total Assets (Q: Jan. 2026 )+Total Assets (Q: Apr. 2026 ))/ count )
=-9.388/( (0.736+1.115)/ 2 )
=-9.388/0.9255
=-1,014.37 %

Note: The Net Income data used here is four times the quarterly (Apr. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Sernova Biotherapeutics's Asset Turnover for the quarter that ended in Apr. 2026 is

Asset Turnover
=Revenue (Q: Apr. 2026 )/( (Total Assets (Q: Jan. 2026 )+Total Assets (Q: Apr. 2026 ))/ count )
=0/( (0.736+1.115)/ 2 )
=0/0.9255
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Sernova Biotherapeutics Total Assets Related Terms

Sernova Biotherapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Sernova Biotherapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sernova Biotherapeutics Total Assets Chart

Sernova Biotherapeutics Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.98 38.34 16.12 5.47 0.55

Sernova Biotherapeutics Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.77 0.67 0.55 0.74 1.12
SEOVF
30GF Score
Sernova Biotherapeutics Inc SEOVF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sernova Biotherapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Sernova Biotherapeutics's Total Assets for the fiscal year that ended in Oct. 2025 is calculated as

Total Assets=Total Equity (A: Oct. 2025 )+Total Liabilities (A: Oct. 2025 )
=-17.928+18.474
=0.55

Sernova Biotherapeutics's Total Assets for the quarter that ended in Apr. 2026 is calculated as

Total Assets=Total Equity (Q: Apr. 2026 )+Total Liabilities (Q: Apr. 2026 )
=-7.009+8.124
=1.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $1.12 Mil mean?
Sernova Biotherapeutics (SEOVF) has a Total Assets of $1.12 Mil as of Apr. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Sernova Biotherapeutics and its competitors.
Is Sernova Biotherapeutics' Total Assets too high?
Sernova Biotherapeutics' current Total Assets is $1.12 Mil. Overall, Sernova Biotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Sernova Biotherapeutics' Total Assets compare to VRTX and REGN?
Sernova Biotherapeutics' Total Assets of $1.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Sernova Biotherapeutics and its competitors. Sernova Biotherapeutics's current Total Assets is $1.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sernova Biotherapeutics stock overvalued right now?
Sernova Biotherapeutics (SEOVF) has a current Total Assets of $1.12 Mil. The current Total Assets is $1.12 Mil. Sernova Biotherapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Sernova Biotherapeutics (SEOVF), the current Total Assets is $1.12 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sernova Biotherapeutics Business Description

Other Exchanges PSH0:GermanySVA:Canada
Address RPO Central Parkway, PO Box 29592, Mississauga, ON, CAN, L5A 4H2
Sernova Biotherapeutics Inc is a clinical-stage biotechnology company focused on advancing regenerative medicine for the treatment of chronic diseases. The Company's primary asset is its proprietary Cell Pouch, a bio-hybrid organ system designed to enhance the delivery of cell therapy by replicating natural body functions. The Cell Pouch creates a vascularized, organ-like environment that promotes the longevity and functionality of therapeutic cells and ensures containment for retrievability.
30GF Score

Get the complete analysis for SEOVF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price